Celiac Disease in Childhood-Adulthood Transition
Launched by TAMPERE UNIVERSITY HOSPITAL · Oct 7, 2021
Trial Information
Current as of November 11, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study, called CeliCAT (Celiac Disease in Childhood-Adulthood Transition), is a randomized trial in Finnish teens aged 13–19 who were diagnosed with celiac disease in childhood. It tests whether using a structured transition form to guide moving from pediatric to adult care improves outcomes compared with routine practices. About half of the participants will receive the structured transition support (the CeliCAT form) and the other half will follow usual care. The researchers will look at whether this approach helps teens stay on a gluten-free diet, become more ready to transition to adult care, and feel better about their overall health and quality of life. They will collect information through questionnaires, blood tests for celiac antibodies, and urine tests for gluten exposure, with follow-ups at 1 year and 3 years.
Who can participate and what to expect: in addition to 13–19-year-olds with a confirmed childhood diagnosis of celiac disease, the study includes a control group of peers without celiac disease. Key eligibility for the celiac group is being Finnish-speaking and able to complete questionnaires; those unable to complete the questionnaires are excluded. The study is being conducted at several Finnish hospitals, led by Tampere University Hospital, with involvement from other universities and centers. Participants will have visits at the start of the study and at 1 year and 3 years, including questionnaires and some blood and urine tests, to help researchers learn how best to support teens as they move into adult healthcare.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • verified celiac disease diagnosis in childhood (\<16 years of age)
- • age 13-19 years at recruitment
- • Finnish-speaking
- Exclusion Criteria:
- • disease or condition preventing the completing of the study questionnaire
- • Inclusion criteria for controls
- • no celiac disease diagnosis
- • age 13-19 years at recruitment
- • Finnish-speaking
About Tampere University Hospital
Tampere University Hospital (TAYS) is a leading academic medical center in Finland, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, TAYS integrates cutting-edge medical practices with rigorous scientific investigation, focusing on improving patient outcomes and enhancing treatment modalities across various specialties. The hospital collaborates with a network of researchers, healthcare professionals, and academic institutions to foster a multidisciplinary approach to medical research, ensuring that findings are translated into real-world applications for the benefit of patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lappeenranta, Finland
Kuopio, Finland
Seinäjoki, Finland
Turku, Finland
Tampere, Finland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials